H.R. 5334 (112th): To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies.

Introduced:

May 7, 2012
112th Congress, 2011–2013

Status:
Died in a previous Congress

This bill was introduced on May 7, 2012, in a previous session of Congress, but was not enacted.

Sponsor:

Brian Bilbray
Representative for California's 50th congressional district
Republican

Text:

Read Text »
Last Updated: May 7, 2012
Length: 8 pages

About the bill

Summary (CRS)
5/7/2012--Introduced.Amends the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services (HHS), at the request of the sponsor of a drug, to expedite the ...

Read more >

Related Bills

Legislative action may be ocurring on one of these bills in lieu of or in parallel to action on this bill.

S. 3187 (Related)
Food and Drug Administration Safety and Innovation Act

Enacted — Signed by the President
Jul 9, 2012

H.R. 5651 (Related)
Food and Drug Administration Reform Act of 2012

Passed House
Last Action: May 30, 2012

What is a bill?

The “H.R.” in “H.R. 5334” means this is a House of Representatives bill in the United States Congress. A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

The bill’s title was written by its sponsor.

History

Introduced
May 7, 2012

Details

Cosponsors
1 cosponsors (1D) (show)
Committee Assignments
Health

The committee chair determines whether a bill will move past the committee stage.

Votes

There have been no votes related to this bill.

Links & tools

Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.

Citation

Click a format for a citation suggestion: